Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4303 | White Sender in Acknowledgement Wiki | 0.71 |
| drug237 | African American Sender in Informational Videos. Wiki | 0.71 |
| drug3254 | Racial Inequality Highlighted Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug114 | AMA Acknowledgement Drug Pricing Wiki | 0.71 |
| drug4304 | White Sender in Informational Videos Wiki | 0.71 |
| drug236 | African American Sender Acknowledgement Wiki | 0.71 |
| drug1972 | Interleukin-1 receptor antagonist Wiki | 0.71 |
| drug309 | Anti-SARS-CoV-2 immunoglobulin Wiki | 0.71 |
| drug197 | Acknowledgement Racial Injustice AMA Wiki | 0.71 |
| drug2573 | No Racial Inequality Highlighting Wiki | 0.71 |
| drug2988 | Placebo videos Wiki | 0.71 |
| drug3728 | Standard of Care Wiki | 0.11 |
Navigate: Correlations HPO
There are 2 clinical trials
This study aims to find out whether the use of angiotensin II, which is a drug to raise blood pressure has been approved by European Medical Agency in August 2019, as an add-on medication to increase blood pressure in patients with COVID-19, acute severe lung injury, inflammation and severe shock, compared with standard medication. In addition, the investigators will collect the data of Anakinra, another drug which is frequently used in this condition to reduce inflammation. The investigators will collect clinical data and outcomes from critical care patients. The investigators will analyse for whom these drugs are most beneficial and explore whether there are any patients who don't benefit or have side effects.
Description: Percentage
Measure: Proportions of patients with mean arterial pressure ≥ 65 mmHg or an increase of mean arterial pressure ≥10 mmHg at 3 hours Time: 3 hoursDescription: microgram/kg/min
Measure: Noradrenaline dose Time: 1 hour and 3 hoursDescription: Changes in score, minimum 0, maximum 24, the higher score showing worse prognosis
Measure: Sequential Organ Failure Assessment (SOFA) score Time: baseline, 24, and 48 hoursDescription: Patients who are alive and do not require renal replacement therapy at 28 days
Measure: RRT-free days Time: 28 daysDescription: Proportions of patients who do not require renal replacement therapy
Measure: RRT discontinuation Time: 7 and 28 daysDescription: micromol/L
Measure: Serum creatinine Time: 7 days and 28 daysDescription: Changes in value
Measure: PaO2/FiO2 ratio Time: baseline, 24, and 48 hoursDescription: Mortality rate
Measure: Mortality Time: 7 days and 28 daysDescription: e.g. arrhythmia, thromboembolism, etc.
Measure: Adverse events Time: 28 daysDescription: Change in serum C-reactive protein
Measure: Change in serum C-reactive protein Time: 7 daysDescription: Change in serum ferritin
Measure: Change in serum ferritin Time: 7 daysSeptic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study. First, angiotensin II is the newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several subgroups from the approval trial have indicated that angiotensin II may confer a survival benefit in certain conditions, including those patients requiring continuous renal replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.
Description: Plasma renin levels will be measured from blood collected at baseline, 24 hours, and at shock resolution. Additionally, a 3-hour measurement will be included in the angiotensin II arm.
Measure: Change in Plasma Renin Levels Time: Until shock resolution, up to 14 days (at baseline, 3 hours, 24 hours, and shock resolution, up to 14 days)Description: Cystatin C, NGAL will be measured from blood collected at baseline, 24 hours, and at shock resolution.
Measure: Change in Renal Biomarkers Time: Until shock resolution, up to 14 days (at baseline, 24 hours, and shock resolution, up to 14 days)Description: Time from enrollment to discontinuation of catecholamines
Measure: Time to discontinuation of catecholamines Time: Until shock resolution, up to 14 daysDescription: Number of days in the intensive care unit (ICU).
Measure: ICU Length of Stay Time: From enrollment to ICU discharge, up to 28 days following enrollmentDescription: Assessment of all-cause mortality within hospital admission
Measure: In-hospital mortality Time: Up to 3 months following enrollmentDescription: Days free of renal replacement therapy from enrollment up to day 28
Measure: Renal replacement therapy-free days Time: Within 28 days of enrollmentDescription: Incidence of venous thromboembolism, arrhythmia, extremity hypoperfusion, delirium, new ischemic event, new infection
Measure: Safety outcomes Time: Up to 72 hours following shock resolution, no longer than 17 days from enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports